KLI

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration

Metadata Downloads
Abstract
Abstract


Objective: To report 2-year efficacy and safety outcomes of 2 dosing regimens of abicipar (every 8 weeks and quarterly, after initial doses) compared with monthly ranibizumab in patients with treatment-naive neovascular age-related macular degeneration (nAMD).

Design: Two multicenter, randomized, phase 3 clinical trials with identical protocols (CEDAR/SEQUOIA). Analyses used pooled trial data.

Participants: The trials enrolled 1888 patients (1 eye/patient) with active choroidal neovascularization secondary to AMD and best-corrected visual acuity (BCVA) of 24-73 Early Treatment Diabetic Retinopathy Study letters.

Methods: At enrollment, patients were assigned to study eye treatment with abicipar 2 mg every 8 weeks after 3 initial doses at baseline and weeks 4 and 8 (abicipar Q8, n = 630), abicipar 2 mg every 12 weeks after 3 initial doses at baseline and weeks 4 and 12 (abicipar Q12, n = 628), or ranibizumab 0.5 mg every 4 weeks (ranibizumab Q4, n = 630).

Main outcome measures: Efficacy measures included stable vision (<15-letter loss in BCVA from baseline) and change from baseline in BCVA and central retinal thickness (CRT). Safety measures included adverse events (AEs).

Results: For patients who completed the study, efficacy of abicipar after initial doses was maintained through week 104. At week 104, the proportion of patients with stable vision was 93.0% (396/426), 89.8% (379/422), and 94.4% (470/498); mean change in BCVA from baseline was +7.8, +6.1, and +8.5 letters, and mean change in CRT from baseline was -147, -146, and -142 μm in the abicipar Q8 (14 injections), abicipar Q12 (10 injections), and ranibizumab Q4 (25 injections) groups, respectively. The overall incidence of intraocular inflammation (IOI) AEs was 15.4%, 15.3%, and 0.3% from baseline through week 52 and 16.2%, 17.6%, and 1.3% from baseline through week 104 in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively.

Conclusions: Two-year results show efficacy of abicipar Q8 and Q12 in nAMD. First onset of IOI events with abicipar was much reduced in the second year and comparable to that with ranibizumab (0.8% and 2.3% vs 1.0%). The extended duration of effect of abicipar allows for quarterly dosing and reduced treatment burden.
Author(s)
윤영희Andrew ChangAndrew J. LoteryCharles C. WykoffDavid R. ChowDerek KunimotoEric SouiedFrancesco BandelloFRANZCOGrace LeHansjurgen AgostiniJenny JiaoKimmie KimMasahito OhjiRahul N. KhuranaRaj K. MaturiRubens BelfortWerner SchmidtXiao-Yan LiYehia Hashad
Issued Date
2021
Type
Article
Keyword
AbiciparAnalysisAnti-VEGFChoroidal neovascularizationDARPin therapeuticIntravitreal injectionMacular degenerationNeovascular age-related macular degenerationPhysiological aspectsRanibizumabTreatment burdenVisual acuity
DOI
10.1016/j.ophtha.2020.11.017
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7667
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2463601585&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Two-Year%20Results%20of%20the%20Phase%203%20Randomized%20Controlled%20Study%20of%20Abicipar%20in%20Neovascular%20Age-Related%20Macular%20Degeneration&amp;offset=0&amp;pcAvailability=true
Publisher
OPHTHALMOLOGY
Location
미국
Language
한국어
ISSN
0161-6420
Citation Volume
128
Citation Number
7
Citation Start Page
1027
Citation End Page
1038
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.